RA CAPITAL MANAGEMENT, L.P. - 02 Dec 2022 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
SLDB
Transactions as of
02 Dec 2022
Net transactions value
+$15,249,996
Form type
4
Filing time
05 Dec 2022, 16:02:32 UTC
Previous filing
21 Nov 2022
Next filing
12 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Award $15,249,996 +2,163,120 +262% $7.05 2,987,644 02 Dec 2022 See footnotes F1, F2, F3, F6
transaction SLDB Common Stock Award +300,412 +10% 3,288,056 02 Dec 2022 See footnotes F2, F3, F4, F6
transaction SLDB Common Stock Award +109,661 109,661 02 Dec 2022 See footnotes F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired from the Issuer pursuant to the Securities Purchase Agreement dated September 29, 2022.
F2 Reflects the Issuer's reverse stock split that occurred on October 27, 2022.
F3 Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F4 Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022.
F5 Held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund").
F6 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Mr. Shah, a Managing Partner of the Adviser, serves on the Issuer's board of directors.